Princeton Alpha Management’s Nektar Therapeutics NKTR Stock Holding History

Princeton Alpha Management’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-1,079	Closed	-$380K	–	255
2017 Q1	$380K	Buy	1,079 +275	+34%	+$61.8K	0.13%	282
2016 Q4	$148K	Buy	+804	New	+$163K	0.03%	630
2015 Q4	–	Sell	-1,261	Closed	-$207K	–	859
2015 Q3	$207K	Buy	+1,261	New	+$223K	0.04%	600

Other funds holding NKTR

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Princeton Alpha Management's NKTR Position: Q2 2017 in Review

Princeton Alpha Management sold out of Nektar Therapeutics (NKTR) in Q2 2017, closing a stake of 1,079 shares — an estimated $380K sold.

Princeton Alpha Management first reported a position in NKTR in Q3 2015 and held it in 3 quarters. The position peaked at $380K in Q1 2017. 197 funds tracked by Wall St. Rank hold NKTR as of Q2 2017.

Princeton Alpha Management reported no remaining Nektar Therapeutics position as of Q2 2017 after selling out during the quarter.
Princeton Alpha Management sold 1,079 Nektar Therapeutics shares in Q2 2017, an estimated $380K.
Princeton Alpha Management first reported a position in Nektar Therapeutics in Q3 2015 and held it in 3 quarters.
Princeton Alpha Management's Nektar Therapeutics position peaked at $380K in Q1 2017.
197 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2017.

Based on Princeton Alpha Management's 13F filing for Q2 2017.